NAD+ side effects and results in studies
Each statement is tied to the study that reported it. Tolerability observations from the cited papers appear below in the authors own terms. Human work of this size does not establish a safety profile.
Adverse events reported
| Event | As reported | Source |
|---|---|---|
| NR was well tolerated and gave a significant but variable rise in brain NAD measured by 31P-MRS, altered cerebral metabolism on FDG-PET in those whose brain NAD rose, and lowered inflammatory cytokines in serum and cerebrospinal fluid. | Human | Brakedal B et al. |
| Pulse wave velocity tended to fall but did not differ significantly from placebo; no adverse events were reported. | Human | Katayoshi T et al. |
| Chronic NR was well tolerated and stimulated NAD+ metabolism; the authors suggest blood pressure and arterial stiffness as outcomes for future trials. | Human | Martens CR et al. |
Outcomes measured
No outcome data are tabulated yet.
What the studies don't show
Nothing here speaks to use outside the trial protocol. Testing establishes identity and purity; it is not evidence of an effect.